Skip to NavigationSkip to content

Kinex Pharmaceuticals appoints Rudolf Kwan

Published on: 02/03/10

Dr Rudolf Kwan has joined Buffalo, US-based  Kinex Pharmaceuticals as chief medical officer.

He will be responsible for the design and execution of the company's clinical development programmes, which in 2010 will include launching several phase II oncology studies for KX2-391 as well as a phase I brain cancer trial for KX2-361.

Kwan has more than twenty years experience in clinical operations and most recently held a dual role at Schering-Plough as VP and regional head of Asia Pacific global clinical operations and VP of global clinical development, CNS.

Before this he held various clinical operation positions with increasing responsibility and held similar positions at Chiron Corporation and at Smith Kline Beecham.

Kwan obtained a medical degree in Hong Kong and subsequently trained in England. He has also served as chair of the data monitoring and safety board for the National Institute on Deafness and other Communication Disorders for trials on celecoxib as an adjunct to surgery for Recurrent Respiratory Papillomatosis.

Currently, he is a member and chair, of the Data Monitoring and Safety Board and Protocol Review Board for the Clinical Trial Network of the National Institute on Drug Abuse (NIDA) of the National Institute of Health. He is also a member of several advisory panels and grant review panels for NIDA.

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches